Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
Executive Summary
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
You may also be interested in...
Merck Solidifies RCC Position, While Bristol Gets Good SubQ Readout
Keytruda becomes the first immuno-oncology agent to show an overall survival benefit in adjuvant renal cell carcinoma. Bristol gains ground on Merck and Roche in race to develop a subcutaneous checkpoint inhibitor.
Gene Techno Collaborates With Kishi Kasei On Aflibercept
Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.
Granules May Be Next Private Equity Target
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for private equity funds.